{"id":18498,"date":"2024-12-17T15:30:25","date_gmt":"2024-12-17T16:30:25","guid":{"rendered":"https:\/\/medexperts.pro\/?p=18498"},"modified":"2024-12-17T17:24:10","modified_gmt":"2024-12-17T17:24:10","slug":"how-openai-plans-to-move-from-being-a-nonprofit","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=18498","title":{"rendered":"How OpenAI Plans to Move From Being a Nonprofit"},"content":{"rendered":"
<\/div>\n

As the maker of ChatGPT battles Google and Meta for A.I. supremacy, it\u2019s also fighting to end control by a nonprofit board.<\/p>\n

\n
\n
\n

Last fall, the nonprofit that controls OpenAI tried to fire<\/a> the company\u2019s high-profile leader, Sam Altman. It failed.<\/p>\n

Ever since then, Mr. Altman has been trying to wrest control of the company away from the nonprofit.<\/p>\n

Under the watchful eyes of government regulators, the press and the public, Mr. Altman and his colleagues are working to sever the nonprofit\u2019s control while ensuring that the existing board is properly compensated for the changes, according to four people familiar with the negotiations who spoke on the condition of anonymity. <\/p>\n

Mr. Altman and his colleagues need to answer a question: What is a fair price for ceding control over a technology that might change the world? Proper compensation to the nonprofit is still being debated, but it could easily be in the billions of dollars, one person said.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

And the clock is ticking for OpenAI\u2019s board of directors. It has promised investors that it will restructure the organization within the next two years, according to documents reviewed by The New York Times.<\/p>\n

\u201cWe are and have been for a while looking at some changes,\u201d Mr. Altman said this month during an appearance at The Times\u2019s DealBook Summit<\/a> in New York. \u201cIt is, as you can imagine, complicated.\u201d<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

As the maker of ChatGPT battles Google and Meta for A.I. supremacy, it\u2019s also fighting to end control by a nonprofit board.Last fall, the nonprofit that controls OpenAI tried to fire the company\u2019s high-profile leader, Sam Altman. It failed.Ever since then, Mr. Altman has been trying to wrest control of the company away from the nonprofit.Under the watchful eyes of government regulators, the press and the public, Mr. Altman and his colleagues are working to sever the nonprofit\u2019s control while ensuring that the existing board is properly compensated for the changes, according to four people familiar with the negotiations who spoke on the condition of anonymity. Mr. Altman and his colleagues need to answer a question: What is a fair price for ceding control over a technology that might change the world? Proper compensation to the nonprofit is still being debated, but it could easily be in the billions of dollars, one person said.And the clock is ticking for OpenAI\u2019s board of directors. It has promised investors that it will restructure the organization within the next two years, according to documents reviewed by The New York Times.\u201cWe are and have been for a while looking at some changes,\u201d Mr. Altman said this month during an appearance at The Times\u2019s DealBook Summit in New York. \u201cIt is, as you can imagine, complicated.\u201dWe are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":18500,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-18498","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/18498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18498"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/18498\/revisions"}],"predecessor-version":[{"id":18501,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/18498\/revisions\/18501"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/18500"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}